{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T07:54:03Z","timestamp":1781682843337,"version":"3.54.5"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"DOI":"10.1007\/s11011-026-01900-1","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T07:18:09Z","timestamp":1781680689000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PCSK9 in bridging metabolism and neurodegeneration: a new paradigm for alzheimer\u2019s treatment"],"prefix":"10.1007","volume":"41","author":[{"given":"Shreya","family":"Sood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shareen","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thakur Gurjeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"1900_CR1","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3389\/fnagi.2019.00120","volume":"11","author":"MP Adorni","year":"2019","unstructured":"Adorni MP, Ruscica M, Ferri N et al (2019) Proprotein convertase subtilisin\/kexin type 9, brain cholesterol homeostasis and potential implication for Alzheimer\u2019s disease. Front Aging Neurosci 11:120. https:\/\/doi.org\/10.3389\/fnagi.2019.00120","journal-title":"Front Aging Neurosci"},{"key":"1900_CR2","doi-asserted-by":"publisher","first-page":"e70231","DOI":"10.1002\/ddr.70231","volume":"87","author":"M Alanazi","year":"2026","unstructured":"Alanazi M, Al-Kuraishy HM, Hussain NR et al (2026) Targeting of PCSK9 in the management of Alzheimer\u2019s disease: expanding the new potential key player. Drug Dev Res 87:e70231. https:\/\/doi.org\/10.1002\/ddr.70231","journal-title":"Drug Dev Res"},{"key":"1900_CR3","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1038\/s41380-024-02504-w","volume":"29","author":"M Alonso","year":"2024","unstructured":"Alonso M, Petit AC, Lledo PM (2024) The impact of adult neurogenesis on affective functions: of mice and men. Mol Psychiatry 29:2527\u20132542. https:\/\/doi.org\/10.1038\/s41380-024-02504-w","journal-title":"Mol Psychiatry"},{"key":"1900_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s12017-025-08832-6","volume":"27","author":"EA Alzarea","year":"2025","unstructured":"Alzarea EA, Al-Kuraishy HM, Al-Gareeb AI et al (2025) The conceivable role of metabolic syndrome in the pathogenesis of Alzheimer\u2019s disease: cellular and subcellular alterations in underpinning a tale of two. Neuromolecular Med 27:35. https:\/\/doi.org\/10.1007\/s12017-025-08832-6","journal-title":"Neuromolecular Med"},{"key":"1900_CR102","doi-asserted-by":"publisher","first-page":"e70235","DOI":"10.1002\/alz.70235","volume":"21","author":"Alzheimer\u2019s Association","year":"2025","unstructured":"Alzheimer\u2019s Association (2025) 2025 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 21:e70235. https:\/\/doi.org\/10.1002\/alz.70235","journal-title":"Alzheimers Dement"},{"key":"1900_CR103","doi-asserted-by":"publisher","unstructured":"Amorosi A, Varret M (2026) PCSK9 in vascular smooth muscle cells: biology, pathology, and inhibition to fight atherosclerosis. Atheroscler Plus 11;64:9\u201323. https:\/\/doi.org\/10.1016\/j.athplu.2025.12.001","DOI":"10.1016\/j.athplu.2025.12.001"},{"key":"1900_CR5","doi-asserted-by":"publisher","first-page":"e010838","DOI":"10.1161\/JAHA.118.010838","volume":"8","author":"N Apaijai","year":"2019","unstructured":"Apaijai N, Moisescu DM, Palee S et al (2019) Pretreatment with PCSK9 inhibitor protects the brain against cardiac ischemia\/reperfusion injury through a reduction of neuronal inflammation and amyloid beta aggregation. J Am Heart Assoc 8:e010838. https:\/\/doi.org\/10.1161\/JAHA.118.010838","journal-title":"J Am Heart Assoc"},{"key":"1900_CR6","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1007\/s11886-022-01782-6","volume":"24","author":"N Arnold","year":"2022","unstructured":"Arnold N, Koenig W (2022) PCSK9 inhibitor wars: how does inclisiran fit in with current monoclonal antibody inhibitor therapy? Considerations for patient selection. Curr Cardiol Rep 24:1657\u20131667. https:\/\/doi.org\/10.1007\/s11886-022-01782-6","journal-title":"Curr Cardiol Rep"},{"key":"1900_CR7","doi-asserted-by":"publisher","first-page":"108470","DOI":"10.1016\/j.abb.2020.108470","volume":"689","author":"B Arunsak","year":"2020","unstructured":"Arunsak B, Pratchayasakul W, Amput P et al (2020) Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitor exerts greater efficacy than atorvastatin on improvement of brain function and cognition in obese rats. Arch Biochem Biophys 689:108470. https:\/\/doi.org\/10.1016\/j.abb.2020.108470","journal-title":"Arch Biochem Biophys"},{"key":"1900_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41392-023-01690-3","volume":"9","author":"X Bao","year":"2024","unstructured":"Bao X, Liang Y, Chang H et al (2024) Targeting proprotein convertase subtilisin\/kexin type 9 (PCSK9): from bench to bedside. Signal Transduct Target Ther 9:12. https:\/\/doi.org\/10.1038\/s41392-023-01690-3","journal-title":"Signal Transduct Target Ther"},{"key":"1900_CR9","doi-asserted-by":"publisher","first-page":"48865","DOI":"10.1074\/jbc.M409699200","volume":"279","author":"S Benjannet","year":"2004","unstructured":"Benjannet S, Rhainds D, Essalmani R et al (2004) NARC-1\/PCSK9 and its natural mutants. J Biol Chem 279:48865\u201348875. https:\/\/doi.org\/10.1074\/jbc.M409699200","journal-title":"J Biol Chem"},{"key":"1900_CR11","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1002\/cyto.a.20346","volume":"69","author":"B Bingham","year":"2006","unstructured":"Bingham B, Shen R, Kotnis S et al (2006) Proapoptotic effects of NARC 1 (=\u2009PCSK9), the gene encoding a novel serine proteinase. Cytometry A 69:1123\u20131131. https:\/\/doi.org\/10.1002\/cyto.a.20346","journal-title":"Cytometry A"},{"key":"1900_CR12","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/cvr\/cvad159","volume":"120","author":"M Borrell-Pages","year":"2024","unstructured":"Borrell-Pages M, Luquero A, Vilahur G et al (2024) Canonical Wnt pathway and the LDL receptor superfamily in neuronal cholesterol homeostasis and function. Cardiovasc Res 120:140\u2013151. https:\/\/doi.org\/10.1093\/cvr\/cvad159","journal-title":"Cardiovasc Res"},{"key":"1900_CR13","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jalz.2016.02.010","volume":"12","author":"V Calsolaro","year":"2016","unstructured":"Calsolaro V, Edison P (2016) Neuroinflammation in Alzheimer\u2019s disease: current evidence and future directions. Alzheimers Dement 12:719\u2013732. https:\/\/doi.org\/10.1016\/j.jalz.2016.02.010","journal-title":"Alzheimers Dement"},{"key":"1900_CR15","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.3390\/molecules27061816","volume":"27","author":"ZR Chen","year":"2022","unstructured":"Chen ZR, Huang JB, Yang SL, Hong FF (2022) Role of cholinergic signaling in Alzheimer\u2019s disease. Molecules 27:1816. https:\/\/doi.org\/10.3390\/molecules27061816","journal-title":"Molecules"},{"key":"1900_CR14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12974-023-02905-8","volume":"20","author":"Y Chen","year":"2023","unstructured":"Chen Y, Joo J, Chu JMT et al (2023) Downregulation of the glucose transporter GLUT1 in the cerebral microvasculature contributes to postoperative neurocognitive disorders in aged mice. J Neuroinflammation 20:237. https:\/\/doi.org\/10.1186\/s12974-023-02905-8","journal-title":"J Neuroinflammation"},{"key":"1900_CR16","doi-asserted-by":"publisher","first-page":"1237458","DOI":"10.3389\/fnmol.2023.1237458","volume":"16","author":"R Comaposada-Bar\u00f3","year":"2023","unstructured":"Comaposada-Bar\u00f3 R, Benito-Mart\u00ednez A, Escribano-Saiz JJ et al (2023) Cholinergic neurodegeneration and cholesterol metabolism dysregulation by constitutive p75NTR signaling in the p75exonIII-KO mice. Front Mol Neurosci 16:1237458. https:\/\/doi.org\/10.3389\/fnmol.2023.1237458","journal-title":"Front Mol Neurosci"},{"key":"1900_CR17","doi-asserted-by":"publisher","first-page":"107424842211001","DOI":"10.1177\/10742484221100107","volume":"27","author":"C Coppinger","year":"2022","unstructured":"Coppinger C, Movahed MR, Azemawah V et al (2022) A comprehensive review of PCSK9 inhibitors. J Cardiovasc Pharmacol Ther 27:10742484221100107. https:\/\/doi.org\/10.1177\/10742484221100107","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"1900_CR18","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.3233\/JAD-170993","volume":"62","author":"H Courtemanche","year":"2018","unstructured":"Courtemanche H, Bigot E, Pichelin M et al (2018) PCSK9 concentrations in cerebrospinal fluid are not specifically increased in Alzheimer\u2019s disease. J Alzheimers Dis 62:1519\u20131525. https:\/\/doi.org\/10.3233\/JAD-170993","journal-title":"J Alzheimers Dis"},{"key":"1900_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","volume":"38","author":"J Cummings","year":"2024","unstructured":"Cummings J, Osse AML, Cammann D et al (2024) Anti-amyloid monoclonal antibodies for the treatment of Alzheimer\u2019s disease. BioDrugs 38:5\u201322. https:\/\/doi.org\/10.1007\/s40259-023-00633-2","journal-title":"BioDrugs"},{"key":"1900_CR20","doi-asserted-by":"publisher","first-page":"e14463","DOI":"10.1111\/cns.14463","volume":"30","author":"S Davoody","year":"2024","unstructured":"Davoody S, Asgari Taei A, Khodabakhsh P, Dargahi L (2024) mTOR signaling and Alzheimer\u2019s disease: what we know and where we are? CNS Neurosci Ther 30:e14463. https:\/\/doi.org\/10.1111\/cns.14463","journal-title":"CNS Neurosci Ther"},{"key":"1900_CR21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s11033-023-09021-z","volume":"51","author":"R Dhapola","year":"2024","unstructured":"Dhapola R, Beura SK, Sharma P et al (2024) Oxidative stress in Alzheimer\u2019s disease: current knowledge of signaling pathways and therapeutics. Mol Biol Rep 51:90. https:\/\/doi.org\/10.1007\/s11033-023-09021-z","journal-title":"Mol Biol Rep"},{"key":"1900_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11010-019-03625-5","volume":"463","author":"Q Dong","year":"2020","unstructured":"Dong Q, Majumdar G, O\u2019Meally RN et al (2020) Insulin-induced de novo lipid synthesis occurs mainly via mTOR-dependent regulation of proteostasis of SREBP-1c. Mol Cell Biochem 463:13\u201331. https:\/\/doi.org\/10.1007\/s11010-019-03625-5","journal-title":"Mol Cell Biochem"},{"key":"1900_CR23","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1007\/s11011-025-01631-9","volume":"40","author":"R Ebrahimi","year":"2025","unstructured":"Ebrahimi R, Shahrokhi Nejad S, Falah Tafti M et al (2025) Microglial activation as a hallmark of neuroinflammation in Alzheimer\u2019s disease. Metab Brain Dis 40:1631. https:\/\/doi.org\/10.1007\/s11011-025-01631-9","journal-title":"Metab Brain Dis"},{"key":"1900_CR24","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/13872877251377793","volume":"108","author":"S Fakorede","year":"2025","unstructured":"Fakorede S, Sodiq TA, Ajagbe AO et al (2025) Interplay of GLUT1 alteration and Alzheimer\u2019s disease: a narrative review on glucose transport and energy metabolism. J Alzheimers Dis 108:470\u2013486. https:\/\/doi.org\/10.1177\/13872877251377793","journal-title":"J Alzheimers Dis"},{"key":"1900_CR25","doi-asserted-by":"publisher","first-page":"690372","DOI":"10.3389\/fnagi.2021.690372","volume":"13","author":"FM Feringa","year":"2021","unstructured":"Feringa FM, van der Kant R (2021) Cholesterol and Alzheimer\u2019s disease: from risk genes to pathological effects. Front Aging Neurosci 13:690372. https:\/\/doi.org\/10.3389\/fnagi.2021.690372","journal-title":"Front Aging Neurosci"},{"key":"1900_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3389\/fnins.2019.00629","volume":"13","author":"S Gabbouj","year":"2019","unstructured":"Gabbouj S, Ryh\u00e4nen S, Marttinen M et al (2019) Altered insulin signaling in Alzheimer\u2019s disease brain: special emphasis on PI3K-Akt pathway. Front Neurosci 13:629. https:\/\/doi.org\/10.3389\/fnins.2019.00629","journal-title":"Front Neurosci"},{"key":"1900_CR27","doi-asserted-by":"publisher","first-page":"106144","DOI":"10.1016\/j.nbd.2023.106144","volume":"182","author":"A Gerasimenko","year":"2023","unstructured":"Gerasimenko A, Baldassari S, Baulac S (2023) mTOR pathway: insights into an established pathway for brain mosaicism in epilepsy. Neurobiol Dis 182:106144. https:\/\/doi.org\/10.1016\/j.nbd.2023.106144","journal-title":"Neurobiol Dis"},{"key":"1900_CR28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/clc.22678","volume":"40","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Mach F, Zavitz K et al (2017) Design and rationale of the EBBINGHAUS trial: a phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background therapy. Clin Cardiol 40:59\u201365. https:\/\/doi.org\/10.1002\/clc.22678","journal-title":"Clin Cardiol"},{"key":"1900_CR29","doi-asserted-by":"publisher","first-page":"937133","DOI":"10.3389\/fnmol.2022.937133","volume":"15","author":"P Goel","year":"2022","unstructured":"Goel P, Chakrabarti S, Goel K et al (2022) Neuronal cell death mechanisms in Alzheimer\u2019s disease: an insight. Front Mol Neurosci 15:937133. https:\/\/doi.org\/10.3389\/fnmol.2022.937133","journal-title":"Front Mol Neurosci"},{"key":"1900_CR30","doi-asserted-by":"publisher","first-page":"779","DOI":"10.4103\/1673-5374.354515","volume":"18","author":"CW Huang","year":"2023","unstructured":"Huang CW, Rust NC, Wu HF, Hart GW (2023) Altered O-GlcNAcylation and mitochondrial dysfunction, a molecular link between brain glucose dysregulation and sporadic Alzheimer\u2019s disease. Neural Regen Res 18:779\u2013783. https:\/\/doi.org\/10.4103\/1673-5374.354515","journal-title":"Neural Regen Res"},{"key":"1900_CR32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12944-019-0965-z","volume":"18","author":"G Hussain","year":"2019","unstructured":"Hussain G, Wang J, Rasul A et al (2019) Role of cholesterol and sphingolipids in brain development and neurological diseases. Lipids Health Dis 18:26. https:\/\/doi.org\/10.1186\/s12944-019-0965-z","journal-title":"Lipids Health Dis"},{"key":"1900_CR31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4103\/1673-5374.375317","volume":"19","author":"G Hussain","year":"2024","unstructured":"Hussain G, Akram R, Anwar H et al (2024) Adult neurogenesis: a real hope or a delusion? Neural Regen Res 19:6\u201315. https:\/\/doi.org\/10.4103\/1673-5374.375317","journal-title":"Neural Regen Res"},{"key":"1900_CR33","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.3390\/cancers13153727","volume":"13","author":"D Jacome Sanz","year":"2021","unstructured":"Jacome Sanz D, Raivola J, Karvonen H et al (2021) Evaluating targeted therapies in ovarian cancer metabolism: novel role for PCSK9 and second generation mTOR inhibitors. Cancers (Basel) 13:3727. https:\/\/doi.org\/10.3390\/cancers13153727","journal-title":"Cancers (Basel)"},{"key":"1900_CR34","doi-asserted-by":"publisher","first-page":"9114","DOI":"10.3390\/ijms23169114","volume":"23","author":"RI Ja\u00e9n","year":"2022","unstructured":"Ja\u00e9n RI, Povo-Retana A, Rosales-Mendoza C et al (2022) Functional crosstalk between PCSK9 internalization and pro-inflammatory activation in human macrophages: role of reactive oxygen species release. Int J Mol Sci 23:9114. https:\/\/doi.org\/10.3390\/ijms23169114","journal-title":"Int J Mol Sci"},{"key":"1900_CR35","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13041-019-0525-5","volume":"12","author":"L Jia","year":"2019","unstructured":"Jia L, Pi\u00f1a-Crespo J, Li Y (2019) Restoring Wnt\/\u03b2-catenin signaling is a promising therapeutic strategy for Alzheimer\u2019s disease. Mol Brain 12:104. https:\/\/doi.org\/10.1186\/s13041-019-0525-5","journal-title":"Mol Brain"},{"key":"1900_CR36","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.6026\/973206300181081","volume":"18","author":"C Jinka","year":"2022","unstructured":"Jinka C, Sainath C, Babu S et al (2022) CRISPR-Cas9 gene editing and human diseases. Bioinformation 18:1081\u20131086. https:\/\/doi.org\/10.6026\/973206300181081","journal-title":"Bioinformation"},{"key":"1900_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/978-981-96-0259-9_3","volume-title":"Multi-factorial approach as a therapeutic strategy for the management of Alzheimer\u2019s disease","author":"GM Jojo","year":"2024","unstructured":"Jojo GM, Johnson J, Kuppusamy G, Karri VVSR (2024) Alzheimer\u2019s disease: epidemiology, etiology, risk factors, and future predictions. Multi-factorial approach as a therapeutic strategy for the management of Alzheimer\u2019s disease. Springer, Singapore, pp 41\u201358. https:\/\/doi.org\/10.1007\/978-981-96-0259-9_3"},{"key":"1900_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12974-023-03001-7","volume":"21","author":"KR Keever","year":"2024","unstructured":"Keever KR, Cui K, Casteel JL et al (2024) Cholinergic signaling via the \u03b17 nicotinic acetylcholine receptor regulates the migration of monocyte-derived macrophages during acute inflammation. J Neuroinflammation 21:17. https:\/\/doi.org\/10.1186\/s12974-023-03001-7","journal-title":"J Neuroinflammation"},{"key":"1900_CR39","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ymthe.2018.10.016","volume":"27","author":"M Khoshnejad","year":"2019","unstructured":"Khoshnejad M, Patel A, Wojtak K et al (2019) Development of novel DNA-encoded PCSK9 monoclonal antibodies as lipid-lowering therapeutics. Mol Ther 27:188\u2013199. https:\/\/doi.org\/10.1016\/j.ymthe.2018.10.016","journal-title":"Mol Ther"},{"key":"1900_CR40","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s00424-020-02441-x","volume":"472","author":"H Koepsell","year":"2020","unstructured":"Koepsell H, De Herder W (2020) Glucose transporters in brain in health and disease. Pflugers Arch 472:1299\u20131343. https:\/\/doi.org\/10.1007\/s00424-020-02441-x","journal-title":"Pflugers Arch"},{"key":"1900_CR41","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40035-020-00221-2","volume":"9","author":"HS Kwon","year":"2020","unstructured":"Kwon HS, Koh SH (2020) Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener 9:42. https:\/\/doi.org\/10.1186\/s40035-020-00221-2","journal-title":"Transl Neurodegener"},{"key":"1900_CR42","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1007\/s00018-012-0977-6","volume":"69","author":"K Kysenius","year":"2012","unstructured":"Kysenius K, Muggalla P, M\u00e4tlik K et al (2012) PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling. Cell Mol Life Sci 69:1903\u20131916. https:\/\/doi.org\/10.1007\/s00018-012-0977-6","journal-title":"Cell Mol Life Sci"},{"key":"1900_CR43","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.tem.2016.12.001","volume":"28","author":"C Lane-Donovan","year":"2017","unstructured":"Lane-Donovan C, Herz J (2017) ApoE, ApoE receptors, and the synapse in Alzheimer\u2019s disease. Trends Endocrinol Metab 28:273\u2013284. https:\/\/doi.org\/10.1016\/j.tem.2016.12.001","journal-title":"Trends Endocrinol Metab"},{"key":"1900_CR44","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1073\/pnas.1000323107","volume":"107","author":"M Laplante","year":"2010","unstructured":"Laplante M, Sabatini DM (2010) mTORC1 activates SREBP-1c and uncouples lipogenesis from gluconeogenesis. Proc Natl Acad Sci U S A 107:3281\u20133282. https:\/\/doi.org\/10.1073\/pnas.1000323107","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1900_CR45","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3390\/metabo12030215","volume":"12","author":"PF Lebeau","year":"2022","unstructured":"Lebeau PF, Platko K, Byun JH et al (2022) The emerging roles of intracellular PCSK9 and their implications in endoplasmic reticulum stress and metabolic diseases. Metabolites 12:215. https:\/\/doi.org\/10.3390\/metabo12030215","journal-title":"Metabolites"},{"key":"1900_CR46","doi-asserted-by":"publisher","first-page":"4857","DOI":"10.1242\/jcs.149302","volume":"127","author":"K Lee","year":"2014","unstructured":"Lee K, Shin Y, Cheng R et al (2014) Receptor heterodimerization as a novel mechanism for the regulation of Wnt\/\u03b2-catenin signaling. J Cell Sci 127:4857\u20134869. https:\/\/doi.org\/10.1242\/jcs.149302","journal-title":"J Cell Sci"},{"key":"1900_CR47","doi-asserted-by":"publisher","first-page":"190","DOI":"10.31083\/j.rcm2505190","volume":"25","author":"LA Leiter","year":"2024","unstructured":"Leiter LA, Hegele RA, Brown V et al (2024) Review of evolocumab for the reduction of LDL cholesterol and secondary prevention of atherosclerotic cardiovascular disease. Rev Cardiovasc Med 25:190. https:\/\/doi.org\/10.31083\/j.rcm2505190","journal-title":"Rev Cardiovasc Med"},{"key":"1900_CR48","doi-asserted-by":"publisher","first-page":"100362","DOI":"10.1016\/j.metop.2025.100362","volume":"26","author":"R Li","year":"2025","unstructured":"Li R, Zhang CX, Liu J, Zhang D (2025) PCSK9-promoted LDLR degradation: recruitment or prevention of essential cofactors? Metabol Open 26:100362. https:\/\/doi.org\/10.1016\/j.metop.2025.100362","journal-title":"Metabol Open"},{"key":"1900_CR49","doi-asserted-by":"publisher","first-page":"102663","DOI":"10.1016\/j.sbi.2023.102663","volume":"82","author":"KY Linde-Garelli","year":"2023","unstructured":"Linde-Garelli KY, Rogala KB (2023) Structural mechanisms of the mTOR pathway. Curr Opin Struct Biol 82:102663. https:\/\/doi.org\/10.1016\/j.sbi.2023.102663","journal-title":"Curr Opin Struct Biol"},{"key":"1900_CR52","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3233\/JAD-161136","volume":"57","author":"LS Liu","year":"2017","unstructured":"Liu LS, Bai XQ, Gao Y et al (2017) PCSK9 promotes oxLDL-induced PC12 cell apoptosis through the Bcl-2\/Bax-caspase 9\/3 signaling pathway. J Alzheimers Dis 57:723\u2013734. https:\/\/doi.org\/10.3233\/JAD-161136","journal-title":"J Alzheimers Dis"},{"key":"1900_CR50","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.3390\/cells11192972","volume":"11","author":"C Liu","year":"2022","unstructured":"Liu C, Chen J, Chen H et al (2022) PCSK9 inhibition: from current advances to evolving future. Cells 11:2972. https:\/\/doi.org\/10.3390\/cells11192972","journal-title":"Cells"},{"key":"1900_CR51","doi-asserted-by":"publisher","first-page":"e30523","DOI":"10.1016\/j.heliyon.2024.e30523","volume":"10","author":"L-C Liu","year":"2024","unstructured":"Liu L-C, Liang J-Y, Liu Y-H et al (2024) The intersection of cerebral cholesterol metabolism and Alzheimer\u2019s disease: mechanisms and therapeutic prospects. Heliyon 10:e30523. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e30523","journal-title":"Heliyon"},{"key":"1900_CR53","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.3390\/cells11193002","volume":"11","author":"V Llorente","year":"2022","unstructured":"Llorente V, Velarde P, Desco M, G\u00f3mez-Gaviro MV (2022) Current understanding of the neural stem cell niches. Cells 11:3002. https:\/\/doi.org\/10.3390\/cells11193002","journal-title":"Cells"},{"key":"1900_CR54","doi-asserted-by":"publisher","first-page":"803894","DOI":"10.3389\/fnins.2021.803894","volume":"15","author":"L Lu","year":"2021","unstructured":"Lu L, Yu X, Cai Y et al (2021) Application of CRISPR\/Cas9 in Alzheimer\u2019s disease. Front Neurosci 15:803894. https:\/\/doi.org\/10.3389\/fnins.2021.803894","journal-title":"Front Neurosci"},{"key":"1900_CR55","doi-asserted-by":"publisher","first-page":"105562","DOI":"10.1016\/j.phrs.2021.105562","volume":"167","author":"N Ma","year":"2021","unstructured":"Ma N, Fan L, Dong Y et al (2021) New PCSK9 inhibitor miR-552-3p reduces LDL-C via enhancing LDLR in high fat diet-fed mice. Pharmacol Res 167:105562. https:\/\/doi.org\/10.1016\/j.phrs.2021.105562","journal-title":"Pharmacol Res"},{"key":"1900_CR56","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1515\/revneuro-2019-0089","volume":"31","author":"A Majdi","year":"2020","unstructured":"Majdi A, Sadigh-Eteghad S, Rahigh Aghsan S et al (2020) Amyloid-\u03b2, tau, and the cholinergic system in Alzheimer\u2019s disease: seeking direction in a tangle of clues. Rev Neurosci 31:391\u2013413. https:\/\/doi.org\/10.1515\/revneuro-2019-0089","journal-title":"Rev Neurosci"},{"key":"1900_CR57","doi-asserted-by":"publisher","first-page":"112460","DOI":"10.1016\/j.biopha.2021.112460","volume":"145","author":"P Marques","year":"2022","unstructured":"Marques P, Domingo E, Rubio A et al (2022) Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players. Biomed Pharmacother 145:112460. https:\/\/doi.org\/10.1016\/j.biopha.2021.112460","journal-title":"Biomed Pharmacother"},{"key":"1900_CR59","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.3390\/pharmaceutics15041268","volume":"15","author":"AD Mazura","year":"2023","unstructured":"Mazura AD, Pietrzik CU (2023) Endocrine regulation of microvascular receptor-mediated transcytosis and its therapeutic opportunities: insights by PCSK9-mediated regulation. Pharmaceutics 15:1268. https:\/\/doi.org\/10.3390\/pharmaceutics15041268","journal-title":"Pharmaceutics"},{"key":"1900_CR58","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00018-022-04237-x","volume":"79","author":"AD Mazura","year":"2022","unstructured":"Mazura AD, Ohler A, Storck SE et al (2022) PCSK9 acts as a key regulator of A\u03b2 clearance across the blood-brain barrier. Cell Mol Life Sci 79:163. https:\/\/doi.org\/10.1007\/s00018-022-04237-x","journal-title":"Cell Mol Life Sci"},{"key":"1900_CR60","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1161\/ATVBAHA.122.318839","volume":"43","author":"FH Meng","year":"2023","unstructured":"Meng FH, Liu S, Xiao J et al (2023) New loss-of-function mutations in PCSK9 reduce plasma LDL cholesterol. Arterioscler Thromb Vasc Biol 43:1219\u20131233. https:\/\/doi.org\/10.1161\/ATVBAHA.122.318839","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1900_CR61","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1124\/jpet.114.214221","volume":"350","author":"T Mitchell","year":"2014","unstructured":"Mitchell T, Chao G, Sitkoff D et al (2014) Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering. J Pharmacol Exp Ther 350:412\u2013424. https:\/\/doi.org\/10.1124\/jpet.114.214221","journal-title":"J Pharmacol Exp Ther"},{"key":"1900_CR62","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2174\/0115672050306008240321034006","volume":"21","author":"K Nagori","year":"2024","unstructured":"Nagori K, Pradhan M, Sharma M et al (2024) Current progress on central cholinergic receptors as therapeutic targets for Alzheimer\u2019s disease. Curr Alzheimer Res 21:50\u201368. https:\/\/doi.org\/10.2174\/0115672050306008240321034006","journal-title":"Curr Alzheimer Res"},{"key":"1900_CR63","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3389\/fnins.2020.00609","volume":"14","author":"EM O\u2019Connell","year":"2020","unstructured":"O\u2019Connell EM, Lohoff FW (2020) Proprotein convertase subtilisin\/kexin type 9 (PCSK9) in the brain and relevance for neuropsychiatric disorders. Front Neurosci 14:609. https:\/\/doi.org\/10.3389\/fnins.2020.00609","journal-title":"Front Neurosci"},{"key":"1900_CR64","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","volume":"146","author":"ML O\u2019Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Giugliano RP, Wiviott SD et al (2022) Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation 146:1109\u20131119. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061620","journal-title":"Circulation"},{"key":"1900_CR65","doi-asserted-by":"publisher","first-page":"12192","DOI":"10.3390\/ijms232012192","volume":"23","author":"B Papotti","year":"2022","unstructured":"Papotti B, Adorni MP, Marchi C et al (2022) PCSK9 affects astrocyte cholesterol metabolism and reduces neuron cholesterol supplying in vitro: potential implications in Alzheimer\u2019s disease. Int J Mol Sci 23:12192. https:\/\/doi.org\/10.3390\/ijms232012192","journal-title":"Int J Mol Sci"},{"key":"1900_CR66","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1177\/13872877241284213","volume":"102","author":"B Papotti","year":"2024","unstructured":"Papotti B, Palumbo M, Adorni MP et al (2024) Influence of APOE4 genotype on PCSK9-lipids association in cerebrospinal fluid and serum of patients in the Alzheimer\u2019s disease continuum. J Alzheimers Dis 102:162\u2013172","journal-title":"J Alzheimers Dis"},{"key":"1900_CR67","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1021\/acschemneuro.4c00299","volume":"15","author":"LM Park","year":"2024","unstructured":"Park LM, Pacher P, Lohoff FW (2024) Targeting oxidative stress in neurodegenerative disorders: a novel role for PCSK9 inhibition? ACS Chem Neurosci 15:2662\u20132664. https:\/\/doi.org\/10.1021\/acschemneuro.4c00299","journal-title":"ACS Chem Neurosci"},{"key":"1900_CR68","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12944-022-01751-6","volume":"21","author":"G P\u00e4th","year":"2022","unstructured":"P\u00e4th G, Perakakis N, Mantzoros CS, Seufert J (2022) PCSK9 inhibition and cholesterol homeostasis in insulin producing \u03b2-cells. Lipids Health Dis 21:151. https:\/\/doi.org\/10.1186\/s12944-022-01751-6","journal-title":"Lipids Health Dis"},{"key":"1900_CR69","doi-asserted-by":"publisher","first-page":"e0220254","DOI":"10.1371\/journal.pone.0220254","volume":"14","author":"C Picard","year":"2019","unstructured":"Picard C, Poirier A, B\u00e9langer S et al (2019) Proprotein convertase subtilisin\/kexin type 9 (PCSK9) in Alzheimer\u2019s disease: a genetic and proteomic multi-cohort study. PLoS ONE 14:e0220254. https:\/\/doi.org\/10.1371\/journal.pone.0220254","journal-title":"PLoS ONE"},{"key":"1900_CR70","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fonc.2014.00064","volume":"4","author":"C Porta","year":"2014","unstructured":"Porta C, Paglino C, Mosca A (2014) Targeting PI3K\/Akt\/mTOR signaling in cancer. Front Oncol 4:64. https:\/\/doi.org\/10.3389\/fonc.2014.00064","journal-title":"Front Oncol"},{"key":"1900_CR71","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1007\/s11011-025-01700-z","volume":"40","author":"A Raza","year":"2025","unstructured":"Raza A, Saleem S, Imran S et al (2025) From metabolic dysregulation to neurodegenerative pathology: the role of hyperglycemia, oxidative stress, and blood-brain barrier breakdown in T2D-driven Alzheimer\u2019s disease. Metab Brain Dis 40:1700. https:\/\/doi.org\/10.1007\/s11011-025-01700-z","journal-title":"Metab Brain Dis"},{"key":"1900_CR72","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1194\/jlr.M014118","volume":"52","author":"E Rousselet","year":"2011","unstructured":"Rousselet E, Marcinkiewicz J, Kriz J et al (2011) PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke. J Lipid Res 52:1383\u20131391. https:\/\/doi.org\/10.1194\/jlr.M014118","journal-title":"J Lipid Res"},{"key":"1900_CR73","doi-asserted-by":"publisher","first-page":"937056","DOI":"10.3389\/fnmol.2022.937056","volume":"15","author":"V Rudajev","year":"2022","unstructured":"Rudajev V, Novotny J (2022) Cholesterol as a key player in amyloid \u03b2-mediated toxicity in Alzheimer\u2019s disease. Front Mol Neurosci 15:937056. https:\/\/doi.org\/10.3389\/fnmol.2022.937056","journal-title":"Front Mol Neurosci"},{"key":"1900_CR74","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3390\/brainsci10060386","volume":"10","author":"O S\u00e1iz-Vazquez","year":"2020","unstructured":"S\u00e1iz-Vazquez O, Puente-Mart\u00ednez A, Ubillos-Landa S et al (2020) Cholesterol and Alzheimer\u2019s disease risk: a meta-meta-analysis. Brain Sci 10:386. https:\/\/doi.org\/10.3390\/brainsci10060386","journal-title":"Brain Sci"},{"key":"1900_CR75","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.stem.2023.01.002","volume":"30","author":"E Salta","year":"2023","unstructured":"Salta E, Lazarov O, Fitzsimons CP et al (2023) Adult hippocampal neurogenesis in Alzheimer\u2019s disease: a roadmap to clinical relevance. Cell Stem Cell 30:120\u2013136. https:\/\/doi.org\/10.1016\/j.stem.2023.01.002","journal-title":"Cell Stem Cell"},{"key":"1900_CR76","doi-asserted-by":"publisher","first-page":"9987","DOI":"10.3390\/ijms22189987","volume":"22","author":"A S\u0229dzikowska","year":"2021","unstructured":"S\u0229dzikowska A, Szablewski L (2021) Insulin and insulin resistance in Alzheimer\u2019s disease. Int J Mol Sci 22:9987. https:\/\/doi.org\/10.3390\/ijms22189987","journal-title":"Int J Mol Sci"},{"key":"1900_CR77","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","volume":"114","author":"NG Seidah","year":"2014","unstructured":"Seidah NG, Awan Z, Chr\u00e9tien M, Mbikay M (2014) PCSK9: a key modulator of cardiovascular health. Circ Res 114:1022\u20131036. https:\/\/doi.org\/10.1161\/CIRCRESAHA.114.301621","journal-title":"Circ Res"},{"key":"1900_CR78","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1080\/17460441.2020.1746266","volume":"15","author":"A Serafino","year":"2020","unstructured":"Serafino A, Giovannini D, Rossi S, Cozzolino M (2020) Targeting the Wnt\/\u03b2-catenin pathway in neurodegenerative diseases: recent approaches and current challenges. Expert Opin Drug Discov 15:803\u2013822. https:\/\/doi.org\/10.1080\/17460441.2020.1746266","journal-title":"Expert Opin Drug Discov"},{"key":"1900_CR79","doi-asserted-by":"publisher","first-page":"1522485","DOI":"10.3389\/fneur.2025.1522485","volume":"16","author":"L Sheng","year":"2025","unstructured":"Sheng L, Zheng X, Ding Z et al (2025) Neurovascular coupling dysfunction in encephalopathy: pathophysiological advances and clinical implications. Front Neurol 16:1522485. https:\/\/doi.org\/10.3389\/fneur.2025.1522485","journal-title":"Front Neurol"},{"key":"1900_CR80","doi-asserted-by":"publisher","first-page":"5314","DOI":"10.3390\/nu14245314","volume":"14","author":"X Shu","year":"2022","unstructured":"Shu X, Wu J, Zhang T et al (2022) Statin-induced geranylgeranyl pyrophosphate depletion promotes PCSK9-dependent adipose insulin resistance. Nutrients 14:5314. https:\/\/doi.org\/10.3390\/nu14245314","journal-title":"Nutrients"},{"key":"1900_CR81","doi-asserted-by":"publisher","first-page":"e70180","DOI":"10.1002\/hbm.70180","volume":"46","author":"S Soltani","year":"2025","unstructured":"Soltani S, Dolatshahi M, Soltani S et al (2025) Relationships between brain glucose metabolism patterns and impaired glycemic status: a systematic review of FDG-PET studies with a focus on Alzheimer\u2019s disease. Hum Brain Mapp 46:e70180. https:\/\/doi.org\/10.1002\/hbm.70180","journal-title":"Hum Brain Mapp"},{"key":"1900_CR82","doi-asserted-by":"publisher","first-page":"A1372","DOI":"10.1016\/S0735-1097(14)61372-3","volume":"63","author":"EA Stein","year":"2014","unstructured":"Stein EA, Kasichayanula S, Turner T et al (2014) LDL cholesterol reduction with BMS-962476, an Adnectin inhibitor of PCSK9: results of a single ascending dose study. J Am Coll Cardiol 63:A1372. https:\/\/doi.org\/10.1016\/S0735-1097(14)61372-3","journal-title":"J Am Coll Cardiol"},{"key":"1900_CR83","doi-asserted-by":"publisher","first-page":"111194","DOI":"10.1016\/j.celrep.2022.111194","volume":"40","author":"Y Sun","year":"2022","unstructured":"Sun Y, Zhang H, Meng J et al (2022) S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K\/AKT pathway. Cell Rep 40:111194. https:\/\/doi.org\/10.1016\/j.celrep.2022.111194","journal-title":"Cell Rep"},{"key":"1900_CR84","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.3390\/life15121851","volume":"15","author":"V Suswidiantoro","year":"2025","unstructured":"Suswidiantoro V, Puteri MU, Kato M et al (2025) The roles of PCSK9 in Alzheimer\u2019s disease: a systematic review of clinical, genetic, and preclinical evidence. Life (Basel) 15:1851. https:\/\/doi.org\/10.3390\/life15121851","journal-title":"Life (Basel)"},{"key":"1900_CR85","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.atherosclerosis.2014.12.017","volume":"238","author":"H Tavori","year":"2015","unstructured":"Tavori H, Rashid S, Fazio S (2015) On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects. Atherosclerosis 238:264\u2013270. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2014.12.017","journal-title":"Atherosclerosis"},{"key":"1900_CR86","doi-asserted-by":"publisher","first-page":"13637","DOI":"10.3390\/ijms252413637","volume":"25","author":"G Testa","year":"2024","unstructured":"Testa G, Giannelli S, Staurenghi E et al (2024) The emerging role of PCSK9 in the pathogenesis of Alzheimer\u2019s disease: a possible target for the disease treatment. Int J Mol Sci 25:13637. https:\/\/doi.org\/10.3390\/ijms252413637","journal-title":"Int J Mol Sci"},{"key":"1900_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10753-022-01721-1","volume":"46","author":"S Thakur","year":"2023","unstructured":"Thakur S, Dhapola R, Sarma P et al (2023) Neuroinflammation in Alzheimer\u2019s disease: current progress in molecular signaling and therapeutics. Inflammation 46:1\u201317. https:\/\/doi.org\/10.1007\/s10753-022-01721-1","journal-title":"Inflammation"},{"key":"1900_CR88","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41582-023-00815-0","volume":"19","author":"L Traxler","year":"2023","unstructured":"Traxler L, Lucciola R, Herdy JR et al (2023) Neural cell state shifts and fate loss in ageing and age-related diseases. Nat Rev Neurol 19:434\u2013443. https:\/\/doi.org\/10.1038\/s41582-023-00815-0","journal-title":"Nat Rev Neurol"},{"key":"1900_CR89","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.mcn.2010.08.001","volume":"45","author":"C Ullrich","year":"2010","unstructured":"Ullrich C, Pirchl M, Humpel C (2010) Hypercholesterolemia in rats impairs the cholinergic system and leads to memory deficits. Mol Cell Neurosci 45:408\u2013417. https:\/\/doi.org\/10.1016\/j.mcn.2010.08.001","journal-title":"Mol Cell Neurosci"},{"key":"1900_CR90","doi-asserted-by":"publisher","first-page":"823","DOI":"10.3748\/wjg.v22.i2.823","volume":"22","author":"V Vilchez","year":"2016","unstructured":"Vilchez V, Turcios L, Marti F, Gedaly R (2016) Targeting Wnt\/\u03b2-catenin pathway in hepatocellular carcinoma treatment. World J Gastroenterol 22:823\u2013832. https:\/\/doi.org\/10.3748\/wjg.v22.i2.823","journal-title":"World J Gastroenterol"},{"key":"1900_CR91","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.bbi.2023.11.008","volume":"115","author":"A Vilella","year":"2024","unstructured":"Vilella A, Bodria M, Papotti B et al (2024) PCSK9 ablation attenuates A\u03b2 pathology, neuroinflammation and cognitive dysfunctions in 5XFAD mice. Brain Behav Immun 115:517\u2013534. https:\/\/doi.org\/10.1016\/j.bbi.2023.11.008","journal-title":"Brain Behav Immun"},{"key":"1900_CR92","doi-asserted-by":"publisher","first-page":"115919","DOI":"10.1016\/j.envpol.2020.115919","volume":"273","author":"Z Wei","year":"2021","unstructured":"Wei Z, Nie G, Yang F et al (2021) Inhibition of ROS\/NLRP3\/caspase-1 mediated pyroptosis attenuates cadmium-induced apoptosis in duck renal tubular epithelial cells. Environ Pollut 273:115919. https:\/\/doi.org\/10.1016\/j.envpol.2020.115919","journal-title":"Environ Pollut"},{"key":"1900_CR93","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s13167-017-0106-6","volume":"8","author":"M Wici\u0144ski","year":"2017","unstructured":"Wici\u0144ski M, \u017bak J, Malinowski B et al (2017) PCSK9 signaling pathways and their potential importance in clinical practice. EPMA J 8:391\u2013402. https:\/\/doi.org\/10.1007\/s13167-017-0106-6","journal-title":"EPMA J"},{"key":"1900_CR94","doi-asserted-by":"publisher","first-page":"e17676","DOI":"10.7717\/peerj.17676","volume":"12","author":"Y Yang","year":"2024","unstructured":"Yang Y, Wang Y, Wang Y et al (2024) PCSK9 inhibitor effectively alleviated cognitive dysfunction in a type 2 diabetes mellitus rat model. PeerJ 12:e17676. https:\/\/doi.org\/10.7717\/peerj.17676","journal-title":"PeerJ"},{"key":"1900_CR95","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.3390\/ijms24043506","volume":"24","author":"JH Yoon","year":"2023","unstructured":"Yoon JH, Hwang JH, Son SU et al (2023) How can insulin resistance cause Alzheimer\u2019s disease? Int J Mol Sci 24:3506. https:\/\/doi.org\/10.3390\/ijms24043506","journal-title":"Int J Mol Sci"},{"key":"1900_CR97","doi-asserted-by":"publisher","first-page":"1260921","DOI":"10.3389\/fphar.2023.1260921","volume":"14","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Chen H, Hong L et al (2023) Inclisiran: a new generation of lipid-lowering siRNA therapeutic. Front Pharmacol 14:1260921. https:\/\/doi.org\/10.3389\/fphar.2023.1260921","journal-title":"Front Pharmacol"},{"key":"1900_CR96","doi-asserted-by":"publisher","first-page":"4516","DOI":"10.2174\/0109298673269288231123095215","volume":"32","author":"H Zhang","year":"2025","unstructured":"Zhang H, Xu Q, Zhao Y et al (2025) A novel perspective on PCSK9 in Alzheimer\u2019s disease: a focus on amyloid beta. Curr Med Chem 32:4516\u20134528. https:\/\/doi.org\/10.2174\/0109298673269288231123095215","journal-title":"Curr Med Chem"},{"key":"1900_CR98","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/procel\/pwae026","volume":"16","author":"Q Zheng","year":"2025","unstructured":"Zheng Q, Wang X (2025) Alzheimer\u2019s disease: insights into pathology, molecular mechanisms, and therapy. Protein Cell 16:83\u2013120. https:\/\/doi.org\/10.1093\/procel\/pwae026","journal-title":"Protein Cell"},{"key":"1900_CR99","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3233\/JAD-160411","volume":"55","author":"F Zimetti","year":"2017","unstructured":"Zimetti F, Caffarra P, Ronda N et al (2017) Increased PCSK9 cerebrospinal fluid concentrations in Alzheimer\u2019s disease. J Alzheimers Dis 55:315\u2013320. https:\/\/doi.org\/10.3233\/JAD-160411","journal-title":"J Alzheimers Dis"},{"key":"1900_CR100","doi-asserted-by":"publisher","first-page":"NS20210035","DOI":"10.1042\/NS20210035","volume":"6","author":"T Zorbaz","year":"2022","unstructured":"Zorbaz T, Madrer N, Soreq H (2022) Cholinergic blockade of neuroinflammation: from tissue to RNA regulators. Neuronal Signal 6:NS20210035. https:\/\/doi.org\/10.1042\/NS20210035","journal-title":"Neuronal Signal"},{"key":"1900_CR101","doi-asserted-by":"publisher","unstructured":"Zou A, Sun Y, Dong W et al (2025) Recent progress of sterol regulatory element-binding proteins role in atherosclerosis. Curr Atheroscler Rep 27:74. https:\/\/doi.org\/10.1007\/s11883-025-01317-8https:\/\/doi.org\/10.1016\/J.BBI.2023.11.008","DOI":"10.1007\/s11883-025-01317-8"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-026-01900-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11011-026-01900-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-026-01900-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T07:18:10Z","timestamp":1781680690000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11011-026-01900-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":102,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1900"],"URL":"https:\/\/doi.org\/10.1007\/s11011-026-01900-1","relation":{},"ISSN":["1573-7365"],"issn-type":[{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"137"}}